These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20944800)

  • 21. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project.
    Horninger W; Volgger H; Rogatsch H; Strohmeyer D; Steiner H; Hobisch A; Klocker H; Bartsch G
    J Urol; 2001 Apr; 165(4):1143-5. PubMed ID: 11257656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
    Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R
    Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimum PSA reflex-range.
    Benecchi L
    Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.
    Catalona WJ; Bartsch G; Rittenhouse HG; Evans CL; Linton HJ; Amirkhan A; Horninger W; Klocker H; Mikolajczyk SD
    J Urol; 2003 Dec; 170(6 Pt 1):2181-5. PubMed ID: 14634374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost implications of PSA screening differ by age.
    Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE
    BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS; Goel V; Williams JI; Iscoe NA
    CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brief report: Free prostate-specific antigen test utilization. Consistency with guidelines.
    Jackson BR; Roberts WL
    J Gen Intern Med; 2005 Sep; 20(9):859-61. PubMed ID: 16117757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer.
    Vashi AR; Oesterling JE
    Mayo Clin Proc; 1997 Apr; 72(4):337-44. PubMed ID: 9121181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.
    Raaijmakers R; Blijenberg BG; Finlay JA; Rittenhouse HG; Wildhagen MF; Roobol MJ; Schröder FH
    J Urol; 2004 Jun; 171(6 Pt 1):2245-9. PubMed ID: 15126795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.
    Reissigl A; Horninger W; Fink K; Klocker H; Bartsch G
    Cancer; 1997 Nov; 80(9):1818-29. PubMed ID: 9351555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of percent free prostate-specific antigen measurement on improving the specificity of serum prostate-specific antigen testing in Taiwanese patients.
    Liao CH; Liu SP; Pu YS; Huang CY; Yu HJ; Chen J
    J Formos Med Assoc; 2001 Feb; 100(2):113-9. PubMed ID: 11393098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review.
    Catalona WJ
    Prostate Suppl; 1996; 7():64-9. PubMed ID: 8950366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen.
    Morgan TO; McLeod DG; Leifer ES; Murphy GP; Moul JW
    Urology; 1996 Dec; 48(6A Suppl):76-80. PubMed ID: 8973705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.
    Hayat Roshanai A; Nordin K; Berglund G
    Acta Oncol; 2013 Nov; 52(8):1602-8. PubMed ID: 23421929
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.